US3279996A - Polysiloxane carrier for controlled release of drugs and other agents - Google Patents

Polysiloxane carrier for controlled release of drugs and other agents Download PDF

Info

Publication number
US3279996A
US3279996A US220105A US22010562A US3279996A US 3279996 A US3279996 A US 3279996A US 220105 A US220105 A US 220105A US 22010562 A US22010562 A US 22010562A US 3279996 A US3279996 A US 3279996A
Authority
US
United States
Prior art keywords
drug
silicone rubber
carrier
capsule
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US220105A
Other languages
English (en)
Inventor
Jr David M Long
Folkman Moses Judah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US220105A priority Critical patent/US3279996A/en
Priority to GB33179/63A priority patent/GB998794A/en
Priority to AU34614/63A priority patent/AU274375B2/en
Priority to DE19631467861 priority patent/DE1467861C/de
Priority to FR945914A priority patent/FR1381318A/fr
Priority to CH1061463A priority patent/CH483471A/de
Priority to FR945913A priority patent/FR8424M/fr
Priority to BR152320/63A priority patent/BR6352320D0/pt
Application granted granted Critical
Publication of US3279996A publication Critical patent/US3279996A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/04—Polysiloxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
    • C08G77/18—Polysiloxanes containing silicon bound to oxygen-containing groups to alkoxy or aryloxy groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/20—Polysiloxanes containing silicon bound to unsaturated aliphatic groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
    • C08G77/24—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen halogen-containing groups

Definitions

  • Our invention relates generally to a method and means for introducing a therapeutic agent into a living organism and more particularly, it relates to a polysiloxane carrier that allows for controlled release of drugs and other agents within a specified region or organ of the body.
  • drugs or pharmaceutical preparations have been mixed with carrier agents, such as beeswax, peanut oil, stearates, etc., and injected intra-muscularly into the body.
  • carrier agents such as beeswax, peanut oil, stearates, etc.
  • Such carriers do not give satisfactory results because they often produce undesirable effects, such as foreign body reaction and scar formation; in addition, granulomas (benign fibrous tumors) and sterile abscesses are formed at the site of the injection.
  • the rate of release of the therapeutic agent is so rapid that frequent injections become necessary with only small amounts of active agent in each injection.
  • the bulk of the carrier substance limits the amount of active agent that may be used in each injection.
  • a further practical drawback to this form of introducing medication follows from the fact that injections are active for only a few days or a week.
  • containers of many types have been designed for use within the body cavities whereby medical preparations are allowed to escape from the containers through tiny openings or perforations.
  • tiny openings and perforations are rapidly plugged with body tissues, and the dispensing action ceases in a matter of hours or a few days.
  • More elaborate arrangements for depositing medication within the body involved the use of a dense tablet form which is formed with a smooth, compact surface, a portion of said surface is covered with a protective, undissolvable coating, while the remaining surface of tablet is exposed to the action of the body fluids.
  • resorption of medication from an exposed surface in which the medicinal substance is accessible to fluids cannot be definitely controlled or predicted during dissolution of the entire tablet.
  • novel implantate that is capable of providing a uniform release of powerful drugs for long periods, as much as several years.
  • the novel implantate can release the desired amount of active agent directly into a malfunctioning organ for immediate use and at a constant dosage rate, without interruptions or variations in the supply as is generally the case with all of the previous methods noted above.
  • the desired medication is made readily available in situ from an implanted carrier which releases the active agent in relatively minute amounts yet cumulatively the agent released in a sustained time interval may reach any effective dosage level.
  • the novel carrier of our invention can also be maintained within the body as an active dispenser of medication throughout the body system and to function effectively for prolonged periods without ill effects, whereby the implanted carrier becomes virtually an artificial gland.
  • Another object of the present invention is to provide a novel drug carrier which can be implanted into the body for long term, direct application of a drug without the disadvantages of frequent injections or by way of digestion and absorption.
  • Another object of the invention is to provide a chemical pacemaker for regulating the functions of the heart by means of a slow, prolonged release of a powerful drug.
  • a further object of the invention is to provide an implantate within the body that releases a drug at a predetermined rate based upon pharmaceutical requirements.
  • a still further object of the invention resides in the use of a carrier within the body for slow prolonged release of a dry, powdered drug in situ thereby preserving the drug in its more stable form until it is made available to the body.
  • a further object of the invention is to provide a substantial increase in efficiency in the use of drugs and other agents which have a beneficial effect for a certain organ or region of the animal organism, by encapsulating said drugs to dispense them directly in the designated organ or body region at a therapeutic nate.
  • FIG. 1 is a perspective view, partly in section, of a preferred embodiment of the present invention
  • FIG. 2 is a perspective view illustrating a modification of the drug carrier shown in FIG. 1;
  • FIG. 3 shows a further modification of the invention in which the implantate is in the form of an artificial aortic valve
  • FIG. 4 shows a oardiograph of a heart beat indicating restored heart function as a result of an implanted drug carrier
  • FIG. 5 shows a drug carrier in accordance with the invention implanted in the muscle of the heart.
  • a drug carrier may be formed in the shape of a container, capsule, or medicated solid which contains within an enclosed space or structure thereof a suitable drug for the purpose of implanting said carrier and drug within a living organism.
  • the capsule or other carrier is implanted within the tissues of an organ or in a particular region of the body for controlled release of the drug at a substantially constant level of dosage and for a long duration.
  • drug is used in the specification and claims hereof in its broad sense as synonymous to therapeutic agent, medicament and the like, and it is to be understood that all of such terms are intended to be inclusive of hormones, vitamins, antibiotics, anticoagulants, cancericidal agents, spermicidal agents, vasoactive agents and other medicinals and medications effective to treat undesirable conditions existing in or on an animal body or in the body fluids.
  • a preferred form of our invention comprises a drug carrier formed of an organopolysiloxane rubber composition (more generically known as a silicone rubber), which is non-reactive toward the drug, non-toxic to the body, and known to be compatible with living tissue even after prolonged implantation in the living organism.
  • the silicone can be either a conventional silicone rubber, or a composition chaarcterized by room temperature vulcanizing, i.e., RTV silicone rubber.
  • Either form of silicone rubber can be fabricated into a suitable container, such as hollow tubing, capsule, pellet and the like, or alternately, the silicone rubber may be formed into a prosthetic device capable of retaining within its polymer structure a suitable medication.
  • Another embodiment of our invention is the direct injection of an RTV silicone rubber-drug fluid mixture into a body tissue, as explained in greater detail further on in the specification.
  • the silicone rubber carrier in accordance with the present invention permits slow passage or diffusion of the drug contained therein to the outer surface of the polymer wall where it is absorbed by the body fluids.
  • the drug is preferably used in the dry, powdered form, since the solid form as a rule is found to be more stable, and the drug composition is thus advantageously stored within the body until it is released from the polymer carrier.
  • the invention in its broadest aspect is directed to the phenomenon of diffusion in which a powder, semi-solid or liquid migrates through a polymer wall at a relatively low rate.
  • the mechanism by which diffusion or migrating action is achieved may be explained on the basis of a gradient effect in which the enclosed substance relieves its internal concentration by spreading out into the adjacent medium. This action ordinarily would cease when suflicient substance has reached the outer surface or boundary of the adjacent medium.
  • the migrant molecules are advantageously being removed from the outer surface of the polymer wall by body fluids and by tissue absorption, and the migrating action continues indefinitely, or until the migrant medicinal substance has been completely consumed.
  • the powders, semi-solids, etc. which are capable of penetrating the polymer wall are generally those that show appreciable solubility in the polymer composition. More-over, the ease with which these substances pass interstitially between elastomer molecules will depend to a great extent on the silicone rubber composition which is utilized in the drug carrier.
  • the silicone rubber employed in this invention can be either a conventional one or an RTV type. These rubbery products are now well known in the art.
  • silicone rubber we refer to those sytsems which are converted to the rubbery state (i.e., they are cured or vulcanized) by the action of heat.
  • the silicone polymers in such systems are predominantly linear organopolysiloxanes, having a preferred average degree of substitution of from about 1.98 to 2.02 organic groups attached directly to silicon (by carbon-silicon linkage) per silicon atom.
  • the organic groups attached to silicon are preferably monovalent hydrocarbon radicals such as alkyl, aryl, alkenyl, alkaryl and aralkyl, and of these the methyl, phenyl, and vinyl radicals are most preferred.
  • Halogenated monovalent hydrocarbon radicals may also be present as the organic groups in the silicone polymer, typical examples being chl-orophenyl and 1,1,1-trifluoropropy1 radicals.
  • Variation of the organic groups in the silicone polymer can be used to vary the solubility of the drug in the polymer, and hence can to some extent control the speed of migration of the drug through the polymer.
  • drugs which are insoluble in one type of polymer may be soluble in a different type of polymer. It is obvious that the choice of organic substitution in the polymer should take into consideration any slightly toxic or foreign body reactions brought about by the presence of that polymer in the body. Pure dimethylpolysiloxanes and dimethyl-polysiloxanes which have a minor amount (for example, up to about 0.5 molar percent) of methylvinylsiloxane units present have been studied more extensively from the toxicological standpoint than any others and have been.
  • the conventional silicone rubber formulation usually contains a filler to enhance the tensile strength and other physical properties of the cured rubber.
  • a filler to enhance the tensile strength and other physical properties of the cured rubber.
  • Many types of such fillers are Well known in the art.
  • the socalled reinforcing silica fillers develop the best propertics, however, and silicone rubber containing them has been found to be inert in extensive studies involving implanting the rubber in many different body tissues. For these reasons, the silica fillers are preferred.
  • Examples of reinforcing silica fillers include silica aerogel, fume silica, and other forms of silica having a relatively high pore volume and surface area.
  • the silica fillers can have organosiloxy groups attached to the surface thereof through siloxane bonding to improve the handling properties of the uncured silicone rubber formulation.
  • silicone nubber formulations It is typical of the conventional silicone nubber formulations that they contain a peroxy vulcanizing agent. Again a host of suitable agents is known to the art, but when our invention is to be used by implanting the silicone rubber within the body, we prefer the use of benzoyl peroxide or dichlorobenzoyl peroxide. These agents decompose during the vulcanization and are not present in the finished rubber.
  • the RTV silicone rubbers are also commercially available materials and are known to the art. In general they employ the same silicone polymers as discussed above (although the polymers often contain a greater amount of silicon-bonded hydroxy groups by being deliberately endblocked with such groups).
  • the fillers discussed above can also be used if fillers are desired, and the cross-linking is achieved by introducing components such as the orthosilicates, polysilicates, and siloxanes containing silicon-bonded hydrogen atoms.
  • This type of silicone rubber formulation will cure at room temperature when an appropriate catalyst is added, thus it is at least a two component system in which the catalyst is added just prior to use of the product.
  • the catalysts are metal salts of canboxylic acids, and when the invention is to be used by implanting the silicone rubber within the body, stannous 2-ethylhexoate is the preferred specie of catalyst.
  • silicone rubber sponge composition in the silicone rubber drug-carrier to be used as an anchoring means for the implanted unit, as described in greater detail below.
  • the sponged or foamed type of silicone rubber is also a commercially available product, and can be obtained in an RTV form.
  • Such systems generally employ an organosiloxane polymer containing a relatively great amount of siliconabonded hydroxy groups, another organopolysiloxane polymer containing silicon-bonded hydrogen atoms, and fillers and metal salt catalysts as in the previously discussed RTV systems.
  • the catalyst not only brings about a conversion to the rubbery state, but also releases hydrogen gas from the hydrogen substituted polymer, this gas being the sponging or foaming agent for the system.
  • RTV silicone rubber which can be used in this invention to form a solid (i.e., non-sponged) rubber product is a one component system in the sense that no catalyst need be added.
  • the silicone polymer employed is one which contains two acyloxy group's (preferably acetoxy groups) attached to terminal silicon atoms.
  • the usual fillers can be present in this type of product.
  • the acyloxy groups hydrolyze to form new trifunctional siloxane units within the polymer which act as the cross-linking bridges necessary to produce the final rubbery product.
  • the silicone rubber may bemolded into a capsule or pellet having any convenient wall thickness and containing therein a drug or active agent-one which has bee found to be capable of diifusing into and permeating the silicone rubber wall--the capsule or pellet having a surface substantially free of pores, perforations or semipermeable surface areas.
  • the drug molecules included therein will have a definite or characteristic rate of diffusion through the container wall, which will in effect establish the dosage rate and the amount of drug which is released from a coherent surface in a given time interval.
  • the amount of drug which is released over an extended period is based on the rate at which the drug diffuses through the silicone rubber and also on the ability of the living tissues in the body to absorb the drug from the surface of the container.
  • the amount of drug that reaches the surface may be eifectively controlled.
  • the novel implantate may be varied in many ways, but it is most desirable to shape the dispensing drug carriers into tubular form of given lengths and volume capacity and having a calibrated rate of release for specified drug compositions.
  • Hollow, tubular cartridges or capsules molded into a continuous, uniform dispensing surface and incorporating therein a preferred quantity of active agent may be made available to the medical and surgical profession as standard dispensing units. If it is desired to decrease the amount of drug which is to be released in a given period, a portion of the dispensing silicone rubber surface may be coated with a more impervious plastic substance to limit the effective transference area from which drug diffusion and absorption can occur.
  • a tubular container may be provided with an inner metallic or plastic casing having a number of port holes of a given dimension through which diffusion and transference action of the contained drug may be substantially regulated.
  • Standard implantates of a specified length will provide a prescribed dosage of drug during a 24-hour interval.
  • the implantates may also be designated in terms of desired physiological effects which they are capable of producing:
  • a heart drug in a given tubular length may be prescribed as capable of generating on the average a given number of heart beats, for example, 70, 80, or 90 heart beats per minute.
  • hollow, tubular containers are formed of silicone rubber having a wall thickness sufficient to provide a resilient tubular structure that is self-supporting and that does not collapse or bend while implanted Within the tissues of the body. While the thickness of the container determines initially the time interval which is required for the drug molecules to penetrate the polymer wall, the thickness of the silicone rubber does not affect the dispensing rate of the present carrier. After the drug has penetrated the 6 wall, the migration of drug molecules is primarily a function of the solubility of the drug in the silicone rubber composition, and they will in effect penetrate a thin or thick wall at substantially equal rates.
  • polysiloxane carriers in the form of prosthetic devices for the body into which medication is incorporated by any suitable means.
  • anti-coagulants such as heparin or Versene (ethylenediaminetetraacetic acid) may be impregnated into vascular or intravascular prostheses in order that their relatively slow rate of release from the carrier will provide sufficient protection against thrombosis.
  • the medication may be introduced into the polysiloxane composition during the forming process of the device, or it may be diifused into the finished product.
  • the drug carrier may be formed by immersing the prosthetic device into a saturated solution of herapin, Versene, or other drug in a suitable solvent, such as alcohol, acetone, xylene or water.
  • a mixture of parts by weight of a fluid hydroxy end-blocked dimethylpolysiloxane (having a viscosity of about 10,000 centistrokes 25 C.) and 3 parts of ethylpolysilicate may be combined with 250 grams of penicillin and a suitable catalyst, for example, sta-nnous Z-ethylhexoate in an amount of about 0.5 percent based on the weight of the fluid polysiloxane.
  • a suitable catalyst for example, sta-nnous Z-ethylhexoate in an amount of about 0.5 percent based on the weight of the fluid polysiloxane.
  • the drug carrier of FIG. 1 is a length of silicone rubbing tubing 1, shown in cross-section as comprising a wall 2 and a confined space 3 containing therein an active agent 4, for example, dry vitamin B powder.
  • an active agent 4 for example, dry vitamin B powder.
  • the ends of the tubing are sealed with an RTV silicone rubber 5.
  • the latter consists of methyldiacetoxysilyl end-blocked dimethylpolysiloxane fluid, and a fume silica filler. A period of about 24 hours is necessary for the seals to cure.
  • a specific example of a carrier formed in this manner comprises about 1 cm. length of silicone rubber tubing having an inside diameter of 0.140
  • This rubber was prepared by extruding a mixture of about 75 parts polymer, 24 parts fume silica and 1 part 2,4-dichlorobenzoyl peroxide. The mixture was cured 30 seconds at 730 F. and vulcanized by heating for 2 hours at 400 F.
  • the polymer was a dimethylpolysiloxane containing about 0.14 mole percent methylvinylsiloxane units copolymerized therewith.
  • the tubing is filled with about 20,000 micrograms of tri-iodothyronine.'
  • implantates have been employed in the body and the desired effects produced have been quantitatively correlated.
  • a drug carrier produced in the manner described and containing 10,000 micrograms of a triiodothyronine in a silicone rubber tube having a length of 14 mm. will release approximately 10 micrograms of the drug in a 24-hour period and generally provide a heart rate in a dog of about beats per minute.
  • a drug carrier 24 mm. long is used in the same manner and containing the same drug, it will release approximately 30 micrograms in a 24-hour period, and the heart beat is stepped up to about 200 beats per minute.
  • An implantation involving the use of a heart drug is performed by surgery and involves the insertion of a polysiloxane capsule containing a relatively large amount of dry powder.
  • a capsule containing 30,000 micrograms of digitoxin may be safely utilized within the body without any undue or irregular release of drug.
  • the capsule containing the drug is initially sterilized and all surface digitoxin that may have been released to the surface is carefully removed.
  • the capsule is then implanted by surgery in the myocardium of the heart.
  • the digitoxin is released at a rate of about micrograms per day producing an excitable focus on the heart. This focus then drives the heart at nearly physiologic rates. There is no systemic effect from the use of the drug since it is released in very low concentrations.
  • the drug is dispensed in such low concentrations yet has been found to be effective because the entire drug released in this manner is utilized directly within the heart area. Moreover, the drug need not be sterilized, since migration through the polymer Wall involves molecular size whereas bacteria are many order of magnitude larger and are effectively screened out.
  • FIG. 2 illustrates the use of an open cell silicone rubber sponge layer 6 attached to the capsule surface 1 by any suitable means, as for example, by slipping a sponge sleeve 6 over the capsule surface.
  • the sponge layer has been found to serve as an anchoring means for the capsule within a cavity created in the tissue to receive the capsule; the sponge expands in the cavity and prevents movement of the capsule. Moreover, it serves as a matrix for the absorption of fluid, fibrin or connective tissue in the surrounding areas after implantation. Finally, the sponge layer also acts as a wick for the transport of drug from the capsule surface to the muscle site.
  • an excitable focus is produced, as shown in the cardiograph record of FIG. 4.
  • a fixed heart rate of approximately 55 beats per minute is indicated at A.
  • a sealed silicone rubber tubing (as above described and being approximately 17 mm. long) containing 20,000 micrograms of tri-iodothyronine powder was implanted through an incision 7 in the left ventricle of the heat, as shown in FIG. 5, a heart rate of 150 beats per minute was generated.
  • the electrocardiograph indicates at B the impulses arising from the site of the implant, about 8 hours following the implantation.
  • the implantate may in some cases provide a basal level of drug, while additional dosages may be supplemented by oral medication or by injection.
  • additional dosages may be supplemented by oral medication or by injection.
  • the drug requirements of a patient may be more effectively controlled by providing some of the drug requirement from the implantate, while the practitioner can increase or vary the 1nedication by means of supplemental doses.
  • the capsule may also include more than one drug, one drug which diffuses rapidly becomes quickly available to the body, while a less diffusable drug becomes available at a later time, after the first drug has served its purpose.
  • our method of introducing drugs into the living organism provides a drug carrier which is readily tolerated in living tissues and which does not deteriorate by implantation in the living body. Therefore, the drug carrier may be implanted within the organ or body region to be treated to provide constant release of the drug directly within the region in which it will produce the desired beneficial effect.
  • a capsule containing dry nitrogen mustard may be implanted in (or adjacent to) a cancerous mass.
  • silicone rubber implantate is not dependent upon the gradual decomposition or removal of the carrier.
  • the container or capsule remains intact and unchanged.
  • the active molecule mus-t initially be detached and freed from the carrier as is the case with the use of beeswax or peanut oil, in order for the drug agent to regain its therapeutic effect.
  • the drug employed in the present silicone rubber carrier remains dry even with implantates that have been in use in the body for many months.
  • this method is specifically important for compounds that are highly unstable in the wet form and which could not be utilized effectively by previous means of implantation or injection.
  • a container made of silicone rubber composition as described'herein, which incorporates within the composition a suitable anti-coagulant, such as heparin or Versene.
  • a suitable anti-coagulant such as heparin or Versene.
  • the silicone rubber container of the present invention is use-d to dispense minimum daily amounts of anti-coagulant to the blood thereby obviating the need for large amounts of preservatives.
  • the blood may now be stored for periods of up to 21 days in its normal state, and preferably in accordance with the preferred practice at a temperature of about 4 C., and utilized directly in blood transfusions and for other purposes which require normal, whole blood, relatively free of foreign substances.
  • the invention may be utilized in connection with drug carriers containing any desired medical or pharmaceutical type illustrated for example by any of the anti-infectives.
  • Such preparation include antibacterial-s, i.e., sulfathiozole; antibiotics, i.e., penicillin; antifungal agents; i.e., Nystatin; antimalarials, i.e., atabrine and the antiprotozoans, i.e., hydroxystilbamide isothionate.
  • Antineoplastic agents which include, for example, nitrogen mustard, previously mentioned in the specification; cardiovascular agents, which include digitalis, quinidine and nitroglycerine; con- 9 traceptives, for instance spermicidal agents such as hexylresorcinol, may also be utilized in accordance with the present invention.
  • Hormones and the synthetic substitutes and antagonists as represented by the thyroid hormones and by insulin may be used with beneficial results.
  • Immunological agents including for example, tetanus toxoid, renal acting agents, for example, acetozolomide, skeletal muscle relaxants and their antagonists, for example, Mephenesin, central nervous system stimulants, for example, ephedrine; and central nervous system depressants, which include the barbiturates in all their various chemical modifications are also included in the invention.
  • Anesthetics which may be used in the novel drug carrier, include procaine, an antihistamine, i.e., benadryl; a detoxicant, dimercaprol; an enzyme, i.e., hyaluronidase and an agent affecting blood formation, i.e., liver extract.
  • a radioactive isotope which may be included in the novel carrier is iodine 131-tagged albumen. Specific proteins find utility in accordance with the invention, as represented by gamma globulin.
  • adrenal corticotrophic hormone examples include adrenal corticotrophic hormone; adrenal cortical hormones, such as aldosterone, desoxy corticosterone, hydrocortisone and cortisone; parathromone, pituitrin, testosterone.
  • An implantate for releasing a drug in the tissues of a living organism comprising a drug enclosed in a capsule formed of silicone rubber, said silicone rubber making limited area contact with said drug, said drug being soluble in and capable of diffusing through said silicone rubber to the outer surface of said capsule at a constant rate.
  • a drug carrier capable of releasing a drug at a constant rate when implanted in a living organism comprising a drug enclosed in a sealed container formed of silicone rubber, said drug being soluble in and capable of diffusing through the silicone rubber to the outer surface of said container at a constant rate.
  • a drug carrier capable of releasing a drug at a constant rate when implanted in a living organism comprising a prosthesis formed of silicone rubber, said prosthesis containing therein a drug which is soluble in and capable of diffusing through said silicone rubber to the outer surface of said prosthesis at a constant rate.
  • An implantate for releasing a drug in the tissues of a living organism comprising a drug dispersed in a silicone rubber which has been vulcanized in situ in said tissues, said drug being soluble in and capable of diffusing through said silicone rubber to the outer surface thereof at a constant rate.
  • An implantate for releasing a drug in the tissues of a living organism comprising a capsule formed of silicone rubber, said silicone rubber consisting essentially of dimethylpolysiloxane, and a drug enclosed in said capsule which is soluble in and capable of diffusing through said silicone rubber to the outer surface of said capsule ata constant rate to the outer surface of said capsule at a constant rate.
  • An implantate for releasing a drug in the tissues of a living organism comprising a capsule formed of estrodiol, progesterone and silicone rubber, said silicone rubber consisting essentially of an organopolysiloxane which contains on the average from about 1.98 to about 2.02 organic groups per silicon atom, said group being selected from the radicals consisting of monovalent hydrocarbon radicals and halogenated hydrocarbon radicals, and a drug enclosed in said capsule which is soluble in and capable of diffusing through said silicone rubber to the outer surface of said capsule at a constant rate.
  • An implantate for releasing a drug in the tissues of a living organism comprising a capsule formed of silicone rubber, said silicone rubber consisting essentially of dimethylpolysiloxane, which contains on the average from about 1.98 to about 2.02 organic groups per silicon atom, and up to 0.5 mol percent of methylvinylpolysiloxane, and a drug enclosed in said capsule which is soluble in and capable of diffusing through said silicone rubber to the outer surface of said capsule at a constant rate.
  • a drug carrier capable of releasing a drug at a constant rate when implanted in a living organism comprising a sealed, tubular container and a drug enclosed in said container, said container being formed of a section of silicone rubber tubing and the ends of said tubing being sealed with a layer of silicone rubber, said drug being soluble in and capable of diffusing through said silicone rubber tubing to the outer surface thereof at a constant rate.
  • the method of introducing a drug into an animal body which comprises injecting within a region of said body a mixture of a drug with an organopolysiloxane fluid which undergoes vulcanization at room temperature to silicone rubber, said drug being soluble in and .capable of diffusing through the silicone rubber to the outer surface thereof at a constant rate.
  • a drug carrier which is capable of releasing a drug at a constant rate comprising a sealed, tubular container and a drug within said container, said container being formed of a silicone rubber tubing having an inside diameter of about 0.140 inch and a wall thickness of about 0.030 inch, the ends of said tubing being sealed with a silicone rubber composition, said drug being soluble in and capable of diffusing through said silicone rubber tubing to the outer surface thereof at a constant rate.
  • a drug carrier in accordance with claim 2 including a layer of silicone rubber sponge on the outer surface of said container, said sponge having an open cell structure to provide fluid access to said surface.
  • a method of introducing a drug into an animal body which comprises implanting within the living tissues of said body a capsule formed of silicone rubber and containing a drug which is soluble in and capable of diffusing through said silicone rubber to the outer surface thereof at a constant rate, and allowing said capsule to remain therein for a desired time interval to provide a controlled release of said drug through said silicone rubber.
  • a method of preserving Whole blood with a minimum amount of anti-coagulant which comprises placing said blood in a container formed of silicone rubber, which is impregnated with a solid anti-coagulant composition soluble in and capable of diffusing through said siilcone rubber to the outer surface thereof at a constant rate and storing said blood in said container, said silicone rubber providing a relatively low rate of release of said composition sufiicient to prevent coagulation during storage.
  • a container for storing whole blood comprising a silicone rubber vessel in which the silicone rubber is impregnated with a solid anti-coagulant composition soluble in and capable of diffusing through said silicone rubber to the outer surface thereof at a constant rate to provide a relatively low rate of release of said composition sufficient to prevent coagulation of said blood during storage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
US220105A 1962-08-28 1962-08-28 Polysiloxane carrier for controlled release of drugs and other agents Expired - Lifetime US3279996A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US220105A US3279996A (en) 1962-08-28 1962-08-28 Polysiloxane carrier for controlled release of drugs and other agents
GB33179/63A GB998794A (en) 1962-08-28 1963-08-21 Carrier for controlled release of drugs
AU34614/63A AU274375B2 (en) 1962-08-28 1963-08-26 Polysiloxane carrier for. controlled release of drugs andother agents
DE19631467861 DE1467861C (de) 1962-08-28 1963-08-27 Verwendung von Organopolysiloxan elastomeren als A^zneimitteltrager in fester Form
FR945914A FR1381318A (fr) 1962-08-28 1963-08-28 Procédé de préparation d'un support à base de polysiloxane
CH1061463A CH483471A (de) 1962-08-28 1963-08-28 Träger für chemische Stoffe und dessen Verwendung
FR945913A FR8424M (en:Method) 1962-08-28 1963-08-28
BR152320/63A BR6352320D0 (pt) 1962-08-28 1963-08-28 Dispositivo para uso no interior de tecidos de um organismo vivo processo para preservar o sangue integral e recipiente para armazenar esse ultimo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US220105A US3279996A (en) 1962-08-28 1962-08-28 Polysiloxane carrier for controlled release of drugs and other agents

Publications (1)

Publication Number Publication Date
US3279996A true US3279996A (en) 1966-10-18

Family

ID=22822082

Family Applications (1)

Application Number Title Priority Date Filing Date
US220105A Expired - Lifetime US3279996A (en) 1962-08-28 1962-08-28 Polysiloxane carrier for controlled release of drugs and other agents

Country Status (6)

Country Link
US (1) US3279996A (en:Method)
AU (1) AU274375B2 (en:Method)
BR (1) BR6352320D0 (en:Method)
CH (1) CH483471A (en:Method)
FR (2) FR1381318A (en:Method)
GB (1) GB998794A (en:Method)

Cited By (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365728A (en) * 1964-12-18 1968-01-30 Edwards Lab Inc Upholstered heart valve having a sealing ring adapted for dispensing medicaments
US3371352A (en) * 1965-01-19 1968-03-05 Edwards Lab Inc Heart valve for quick implantation having provision for ingrowth of tissue
US3499445A (en) * 1966-08-16 1970-03-10 Phytogen Prod Inc Animal husbandry
US3511684A (en) * 1967-05-17 1970-05-12 Abbott Lab Method of treating polymeric resin to display nonthrombogenicity
US3548417A (en) * 1967-09-05 1970-12-22 Ronnie G Kischer Heart valve having a flexible wall which rotates between open and closed positions
FR2052973A1 (en:Method) * 1969-06-16 1971-04-16 Reese Hospital Michael
US3576176A (en) * 1969-09-23 1971-04-27 John E P Pickett Cooperative histologic tissue capsule and capsule rack
US3596292A (en) * 1969-02-20 1971-08-03 Franklin Institute Hair implant structure
US3598127A (en) * 1968-06-06 1971-08-10 James G Wepsic Catheter having antibacterial substance therein provided with means permitting slow release of said substance
US3640741A (en) * 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
US3640269A (en) * 1969-10-24 1972-02-08 Jose M R Delgado Fluid-conducting instrument insertable in living organisms
US3659600A (en) * 1970-02-24 1972-05-02 Estin Hans H Magnetically operated capsule for administering drugs
US3678756A (en) * 1969-09-23 1972-07-25 Hans W Estin Capsules and method for testing capsules for wall integrity
US3726972A (en) * 1970-10-27 1973-04-10 Monsanto Co Halosilane-protein crosslink as ruminant feed material
FR2160410A1 (en:Method) * 1971-11-20 1973-06-29 Schering Ag
US3797485A (en) * 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
FR2197582A1 (en) * 1972-09-05 1974-03-29 Moyer Dean Intra-uterine device - for prevention of implantation of blastocysts
US3804088A (en) * 1972-07-31 1974-04-16 Lilly Co Eli Removable implantate for administering physiological active agents to animals
US3811444A (en) * 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3832458A (en) * 1971-12-06 1974-08-27 River C Foundation Hydrophilic silicone composition and method
US3873713A (en) * 1967-06-30 1975-03-25 Hoffmann La Roche Stabilized particulate vitamin c composition
US3898701A (en) * 1974-01-17 1975-08-12 Russa Joseph Implantable heart valve
USRE28536E (en) * 1966-08-16 1975-09-02 Animal husbandry
US3905360A (en) * 1971-11-01 1975-09-16 Alza Corp Intrauterine device for governing the reproductive process
US3911911A (en) * 1969-06-16 1975-10-14 Reese Hospital Michael Anti-fertility device
US3916898A (en) * 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3934274A (en) * 1974-10-29 1976-01-27 Hartley Jr John H Deflatable mammary augmentation prosthesis
US3944064A (en) * 1973-10-26 1976-03-16 Alza Corporation Self-monitored device for releasing agent at functional rate
US3946106A (en) * 1974-10-24 1976-03-23 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US3948262A (en) * 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3967618A (en) * 1969-04-01 1976-07-06 Alza Corporation Drug delivery device
US3971376A (en) * 1973-02-26 1976-07-27 Ceskoslovenska Akademie Ved Method and apparatus for introducing fluids into the body
US3987797A (en) * 1974-02-25 1976-10-26 Ethicon, Inc. Antimicrobial sutures
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4012497A (en) * 1974-09-24 1977-03-15 Schering Aktiengesellschaft Drug excipient of silicone rubber
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
FR2364686A1 (fr) * 1976-09-18 1978-04-14 Merck Patent Gmbh Compositions contenant de l'anhydride silicique et procede pour leur preparation
US4162676A (en) * 1976-08-05 1979-07-31 Dow Corning Corporation Blood bag having co2 absorbent therein
DE2918522A1 (de) * 1978-05-08 1979-11-15 Pfizer Verbessertes system bzw. verbesserte vorrichtung zur kontrollierten und kontinuierlichen abgabe von chemikalien waehrend einer laengeren zeitspanne
US4191741A (en) * 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
US4198976A (en) * 1977-10-11 1980-04-22 The Procter & Gamble Company Vaginal contraceptive
US4200090A (en) * 1979-01-15 1980-04-29 The Procter & Gamble Company Vaginal contraceptive and method of using
US4210644A (en) * 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4219016A (en) * 1978-12-07 1980-08-26 The Procter & Gamble Company Vaginal contraceptive
US4228032A (en) * 1978-11-06 1980-10-14 Dow Corning Corporation Method of storing blood and a blood storage bag therefore
US4264575A (en) * 1979-07-16 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264578A (en) * 1979-07-16 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264577A (en) * 1979-08-03 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264576A (en) * 1979-06-28 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
WO1981001650A1 (en) * 1979-12-17 1981-06-25 Dow Corning Silicone gel-filled silicone rubber article possessing reduced surface-bleed
EP0013949A3 (en) * 1979-01-23 1981-07-22 Hoechst Aktiengesellschaft Depot form based on silicon rubber and method for its preparation
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4301800A (en) * 1978-10-26 1981-11-24 Baxter Travenol Laboratories, Inc. Blood bags having an insert member
US4304226A (en) * 1980-03-03 1981-12-08 The Procter & Gamble Company Vaginal contraceptive
US4304010A (en) * 1978-10-12 1981-12-08 Sumitomo Electric Industries, Ltd. Tubular polytetrafluoroethylene prosthesis with porous elastomer coating
US4309776A (en) * 1980-05-13 1982-01-12 Ramon Berguer Intravascular implantation device and method of using the same
US4321711A (en) * 1978-10-18 1982-03-30 Sumitomo Electric Industries, Ltd. Vascular prosthesis
EP0050867A1 (en) * 1980-10-28 1982-05-05 Schering Aktiengesellschaft Vaginal ring
US4341728A (en) * 1979-12-20 1982-07-27 The Population Council, Inc. Method for making an IUD with shrinking of a medicated attachment onto a support
US4343788A (en) * 1979-06-29 1982-08-10 The Procter & Gamble Company Antimicrobial polymer compositions
US4344431A (en) * 1969-03-24 1982-08-17 University Of Delaware Polymeric article for dispensing drugs
US4384960A (en) * 1979-11-13 1983-05-24 Polley R D Iodine dispenser and method of dispensing iodine
US4392848A (en) * 1979-06-25 1983-07-12 The Procter & Gamble Company Catheterization
US4435180A (en) 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
EP0056697A3 (en) * 1981-01-09 1984-09-19 Robert W. Rand Injectable compositions and apparatus suitable for use in inductively heating neoplasms
US4479795A (en) * 1979-06-29 1984-10-30 The Procter & Gamble Company Antimicrobial polymer compositions
US4485814A (en) * 1979-09-05 1984-12-04 Yoon In B One-piece compound elastic occluding member
US4555398A (en) * 1982-10-05 1985-11-26 Chisso Corporation Sustained-release vasodilator
WO1986001415A1 (en) * 1984-09-06 1986-03-13 Holmes, Michael, John Device for inserting in wounds and wound cavities
WO1987000042A1 (en) * 1985-07-02 1987-01-15 Rutgers, The State University Of New Jersey Transdermal verapamil delivery device
US4731080A (en) * 1985-01-18 1988-03-15 Galin Miles A Coated intraocular lens
EP0219076A3 (en) * 1985-10-11 1988-04-20 Sumitomo Pharmaceuticals Company, Limited Sustained release composition
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
WO1989000839A1 (en) * 1987-07-28 1989-02-09 Biomeasure, Incorporated Therapeutic agent delivery system
GB2216795A (en) * 1988-03-17 1989-10-18 Erba Carlo Spa Controlled release siloxane matrices with non-uniform internal drug distribution
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
US4888009A (en) * 1985-04-05 1989-12-19 Abiomed, Inc. Prosthetic heart valve
WO1989012478A1 (en) * 1988-06-25 1989-12-28 Just Hansjoerg Dilatation catheter
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4951657A (en) * 1988-04-22 1990-08-28 Dow Corning Corporation Heat sealable membrane for transdermal drug release
US4955899A (en) * 1989-05-26 1990-09-11 Impra, Inc. Longitudinally compliant vascular graft
WO1990013332A1 (en) * 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
US4973320A (en) * 1987-08-04 1990-11-27 Firma Carl Freudenberg Tissue-compatible medical device and method for manufacturing the same
US5008112A (en) * 1985-12-16 1991-04-16 International Minerals & Chem. Corporation Device for the extended delivery of diffusible agents
US5100422A (en) * 1989-05-26 1992-03-31 Impra, Inc. Blood vessel patch
US5104400A (en) * 1989-05-26 1992-04-14 Impra, Inc. Blood vessel patch
US5141748A (en) * 1989-02-17 1992-08-25 Hoffmann-La Roche, Inc. Implant drug delivery device
US5152782A (en) * 1989-05-26 1992-10-06 Impra, Inc. Non-porous coated ptfe graft
US5182317A (en) * 1988-06-08 1993-01-26 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
US5219580A (en) * 1989-06-08 1993-06-15 Rhone-Poulenc Chimie Thermoplastic silicone shaped articles for controlled release of iodine values to domestic water supplies
US5262451A (en) * 1988-06-08 1993-11-16 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
US5340583A (en) * 1993-05-06 1994-08-23 Allergan, Inc. Antimicrobial lenses and lens care systems
US5342693A (en) * 1988-06-08 1994-08-30 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coating and methods of manufacture
US5422118A (en) * 1986-11-07 1995-06-06 Pure Pac, Inc. Transdermal administration of amines with minimal irritation and high transdermal flux rate
US5591445A (en) * 1992-12-09 1997-01-07 Regents Of The University Of Minnesota Smooth muscle chemical pacemaker
US5810836A (en) * 1996-03-04 1998-09-22 Myocardial Stents, Inc. Device and method for trans myocardial revascularization (TMR)
WO2000029464A1 (en) * 1998-11-12 2000-05-25 Leiras Oy Novel membrane or matrix for controlling drug permeation
US6168801B1 (en) 1998-09-09 2001-01-02 Cardiac Pacemakers, Inc. Controlled release drug delivery
US6304786B1 (en) 1999-03-29 2001-10-16 Cardiac Pacemakers, Inc. Implantable lead with dissolvable coating for improved fixation and extraction
US20020071902A1 (en) * 1995-04-19 2002-06-13 Ni Ding Drug release stent coating
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US20030195617A1 (en) * 1988-10-04 2003-10-16 Cordis Corporation Expandable intraluminal graft
US6645241B1 (en) 1992-07-08 2003-11-11 Ernst Peter Strecker Endoprosthesis that can be percutaneously implanted in the patient's body
US20040022824A1 (en) * 2002-07-31 2004-02-05 Scimed Life Systems, Inc. Controlled drug delivery
US20040049265A1 (en) * 1995-04-19 2004-03-11 Schneider (Usa) Inc. Drug coating with topcoat
US6756048B1 (en) 1998-09-10 2004-06-29 Sumitomo Pharmaceuticals Company, Limited Long time drug-sustained release preparation
US20040234572A1 (en) * 2001-09-11 2004-11-25 Martinod Serge R. Preparation of sustained release pharmaceutical composition
US20040241204A1 (en) * 2001-06-29 2004-12-02 Martinod Serge R. Sustained release pharmaceutical composition
US20040247643A1 (en) * 2001-06-29 2004-12-09 Martinod Serge R Sustained release delivey system
US20040260272A1 (en) * 2002-10-22 2004-12-23 Friedman Craig D. Method and system for intravesicular delivery of therapeutic agents
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
US20060034943A1 (en) * 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
US20060064082A1 (en) * 2004-09-20 2006-03-23 Bonutti Peter M Minimally invasive therapeutic system
WO2006037182A1 (en) 2004-10-06 2006-04-13 Agri-Biotech Pty Ltd Antibody production method
US20060147371A1 (en) * 2003-10-31 2006-07-06 Tuszynski Jack A Water-soluble compound
US20060282160A1 (en) * 1997-04-18 2006-12-14 Cordis Corporation Local Delivery of Rapamycin for Treatment of Proliferative Sequelae Associated with PTCA Procedures, Including Delivery Using a Modified Stent
US20070141106A1 (en) * 2005-10-19 2007-06-21 Bonutti Peter M Drug eluting implant
US20070166377A1 (en) * 1999-11-10 2007-07-19 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release drug formulations
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7625410B2 (en) 2001-05-02 2009-12-01 Boston Scientific Scimed, Inc. Stent device and method
US20100076113A1 (en) * 2008-09-19 2010-03-25 Mentor Corporation Coating with antimicrobial agents
EP2089486A4 (en) * 2006-11-21 2010-06-16 Steven J Ferry COATING SYSTEM
US7763077B2 (en) 2003-12-24 2010-07-27 Biomerix Corporation Repair of spinal annular defects and annulo-nucleoplasty regeneration
US20100198350A1 (en) * 2008-09-19 2010-08-05 Mentor Worldwide Llc Coating with antimicrobial agents
US7803395B2 (en) 2003-05-15 2010-09-28 Biomerix Corporation Reticulated elastomeric matrices, their manufacture and use in implantable devices
US8067022B2 (en) 1992-09-25 2011-11-29 Boston Scientific Scimed, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US8097642B2 (en) 1995-02-15 2012-01-17 Boston Scientific Scimed, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8303609B2 (en) 2000-09-29 2012-11-06 Cordis Corporation Coated medical devices
US20140021270A1 (en) * 2012-07-19 2014-01-23 National Institute Of Standards And Technology Vapor capture and release systems
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US20160158146A1 (en) * 2001-03-15 2016-06-09 United States of America, Department of Health & Human Services, Represented by the Secretary, C/O Ocular therapeutic agent delivery devices and methods for making and using such devices
WO2019079869A1 (pt) * 2017-10-26 2019-05-02 Sarraff Berger Rodrigo Otavio Implante com reservatório contendo microporos de liberação prolongada para aplicação subdérmica com propriedades termoelásticas e termostática e uso do dito implante
US10286199B2 (en) 2013-03-15 2019-05-14 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
EP3597176A1 (en) 2014-08-19 2020-01-22 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CN114149688A (zh) * 2021-11-19 2022-03-08 北京理工大学 一种肌肉等效材料及其制备方法和应用
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US20230059851A1 (en) * 2014-06-06 2023-02-23 Nanovault Medical Llc Implantable cellular and biotherapeutic agent delivery canister
US11857670B2 (en) 2014-06-06 2024-01-02 Nanovault Medical, Llc Implantable cellular and biotherapeutic agent delivery canister
US11857672B2 (en) 2014-06-06 2024-01-02 Nanovault Medical, Llc Implantable cellular and biotherapeutic agent delivery canister

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3610247A (en) * 1969-03-03 1971-10-05 Richard R Jackson Surface-anesthetizing medical appliance
WO1980002378A1 (en) * 1979-05-03 1980-11-13 Commw Scient Ind Res Org Device for promoting endothelial cell motility and/or vascularisation
FR2562797A1 (fr) * 1984-04-17 1985-10-18 Synkron Corp Implant susceptible de liberer un principe actif
WO1987006828A1 (en) * 1986-05-16 1987-11-19 The State Of Victoria Biocompatible implants
IE58536B1 (en) * 1986-06-09 1993-10-06 Chanelle Chemicals Ltd Subcutaneous implant
US4989601A (en) * 1988-05-02 1991-02-05 Medical Engineering & Development Institute, Inc. Method, apparatus, and substance for treating tissue having neoplastic cells
GB2252497B (en) * 1991-02-04 1995-01-18 Elsimar Metzker Coutinho Pharmaceutical composition

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2504482A (en) * 1949-06-17 1950-04-18 Premo Pharmaceutical Lab Inc Drain-clear container for aqueous-vehicle liquid pharmaceutical preparations
US2512192A (en) * 1948-05-26 1950-06-20 American Cyanamid Co Silicone resin medicament coating
US2846057A (en) * 1954-02-09 1958-08-05 Polin Herbert Spencer Devices for dosage control
US2855933A (en) * 1952-04-04 1958-10-14 American Hospital Supply Corp Fluid receptacle
US2895475A (en) * 1956-12-03 1959-07-21 Everett L Cole Container for collecting, storing and dispensing biological fluids
US2951011A (en) * 1956-12-17 1960-08-30 Feinstone Wolffe Harry Silicone composition for the relief of gastro-intestinal distress and method of using same
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3105613A (en) * 1960-05-09 1963-10-01 Baxter Don Inc Blood container

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512192A (en) * 1948-05-26 1950-06-20 American Cyanamid Co Silicone resin medicament coating
US2504482A (en) * 1949-06-17 1950-04-18 Premo Pharmaceutical Lab Inc Drain-clear container for aqueous-vehicle liquid pharmaceutical preparations
US2855933A (en) * 1952-04-04 1958-10-14 American Hospital Supply Corp Fluid receptacle
US2846057A (en) * 1954-02-09 1958-08-05 Polin Herbert Spencer Devices for dosage control
US2895475A (en) * 1956-12-03 1959-07-21 Everett L Cole Container for collecting, storing and dispensing biological fluids
US2951011A (en) * 1956-12-17 1960-08-30 Feinstone Wolffe Harry Silicone composition for the relief of gastro-intestinal distress and method of using same
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3105613A (en) * 1960-05-09 1963-10-01 Baxter Don Inc Blood container

Cited By (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916898A (en) * 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
US3365728A (en) * 1964-12-18 1968-01-30 Edwards Lab Inc Upholstered heart valve having a sealing ring adapted for dispensing medicaments
US3371352A (en) * 1965-01-19 1968-03-05 Edwards Lab Inc Heart valve for quick implantation having provision for ingrowth of tissue
US3499445A (en) * 1966-08-16 1970-03-10 Phytogen Prod Inc Animal husbandry
USRE28536E (en) * 1966-08-16 1975-09-02 Animal husbandry
US3511684A (en) * 1967-05-17 1970-05-12 Abbott Lab Method of treating polymeric resin to display nonthrombogenicity
US3873713A (en) * 1967-06-30 1975-03-25 Hoffmann La Roche Stabilized particulate vitamin c composition
US3548417A (en) * 1967-09-05 1970-12-22 Ronnie G Kischer Heart valve having a flexible wall which rotates between open and closed positions
US3598127A (en) * 1968-06-06 1971-08-10 James G Wepsic Catheter having antibacterial substance therein provided with means permitting slow release of said substance
US3596292A (en) * 1969-02-20 1971-08-03 Franklin Institute Hair implant structure
US4344431A (en) * 1969-03-24 1982-08-17 University Of Delaware Polymeric article for dispensing drugs
US3967618A (en) * 1969-04-01 1976-07-06 Alza Corporation Drug delivery device
US3948262A (en) * 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3911911A (en) * 1969-06-16 1975-10-14 Reese Hospital Michael Anti-fertility device
FR2052973A1 (en:Method) * 1969-06-16 1971-04-16 Reese Hospital Michael
US3678756A (en) * 1969-09-23 1972-07-25 Hans W Estin Capsules and method for testing capsules for wall integrity
US3576176A (en) * 1969-09-23 1971-04-27 John E P Pickett Cooperative histologic tissue capsule and capsule rack
US3640269A (en) * 1969-10-24 1972-02-08 Jose M R Delgado Fluid-conducting instrument insertable in living organisms
US3659600A (en) * 1970-02-24 1972-05-02 Estin Hans H Magnetically operated capsule for administering drugs
US3640741A (en) * 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
US3726972A (en) * 1970-10-27 1973-04-10 Monsanto Co Halosilane-protein crosslink as ruminant feed material
US3797485A (en) * 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
US3905360A (en) * 1971-11-01 1975-09-16 Alza Corp Intrauterine device for governing the reproductive process
US4230686A (en) * 1971-11-20 1980-10-28 Schering Aktiengesellschaft Drug excipient of silicone rubber
FR2160410A1 (en:Method) * 1971-11-20 1973-06-29 Schering Ag
US3832458A (en) * 1971-12-06 1974-08-27 River C Foundation Hydrophilic silicone composition and method
US3804088A (en) * 1972-07-31 1974-04-16 Lilly Co Eli Removable implantate for administering physiological active agents to animals
FR2197582A1 (en) * 1972-09-05 1974-03-29 Moyer Dean Intra-uterine device - for prevention of implantation of blastocysts
US3811444A (en) * 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3971376A (en) * 1973-02-26 1976-07-27 Ceskoslovenska Akademie Ved Method and apparatus for introducing fluids into the body
US3944064A (en) * 1973-10-26 1976-03-16 Alza Corporation Self-monitored device for releasing agent at functional rate
US3898701A (en) * 1974-01-17 1975-08-12 Russa Joseph Implantable heart valve
US3987797A (en) * 1974-02-25 1976-10-26 Ethicon, Inc. Antimicrobial sutures
US4012497A (en) * 1974-09-24 1977-03-15 Schering Aktiengesellschaft Drug excipient of silicone rubber
DE2547378A1 (de) * 1974-10-24 1976-04-29 Searle & Co Vorrichtung mit abgeschlossenen mikrokammern zur abgabe eines arzneimittels
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US3946106A (en) * 1974-10-24 1976-03-23 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US3934274A (en) * 1974-10-29 1976-01-27 Hartley Jr John H Deflatable mammary augmentation prosthesis
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US4162676A (en) * 1976-08-05 1979-07-31 Dow Corning Corporation Blood bag having co2 absorbent therein
FR2364686A1 (fr) * 1976-09-18 1978-04-14 Merck Patent Gmbh Compositions contenant de l'anhydride silicique et procede pour leur preparation
US4198976A (en) * 1977-10-11 1980-04-22 The Procter & Gamble Company Vaginal contraceptive
US4210644A (en) * 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
DE2918522A1 (de) * 1978-05-08 1979-11-15 Pfizer Verbessertes system bzw. verbesserte vorrichtung zur kontrollierten und kontinuierlichen abgabe von chemikalien waehrend einer laengeren zeitspanne
US4191741A (en) * 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
US4304010A (en) * 1978-10-12 1981-12-08 Sumitomo Electric Industries, Ltd. Tubular polytetrafluoroethylene prosthesis with porous elastomer coating
US4321711A (en) * 1978-10-18 1982-03-30 Sumitomo Electric Industries, Ltd. Vascular prosthesis
US4301800A (en) * 1978-10-26 1981-11-24 Baxter Travenol Laboratories, Inc. Blood bags having an insert member
US4228032A (en) * 1978-11-06 1980-10-14 Dow Corning Corporation Method of storing blood and a blood storage bag therefore
US4219016A (en) * 1978-12-07 1980-08-26 The Procter & Gamble Company Vaginal contraceptive
US4200090A (en) * 1979-01-15 1980-04-29 The Procter & Gamble Company Vaginal contraceptive and method of using
EP0013949A3 (en) * 1979-01-23 1981-07-22 Hoechst Aktiengesellschaft Depot form based on silicon rubber and method for its preparation
US4392848A (en) * 1979-06-25 1983-07-12 The Procter & Gamble Company Catheterization
US4264576A (en) * 1979-06-28 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4343788A (en) * 1979-06-29 1982-08-10 The Procter & Gamble Company Antimicrobial polymer compositions
US4479795A (en) * 1979-06-29 1984-10-30 The Procter & Gamble Company Antimicrobial polymer compositions
US4264578A (en) * 1979-07-16 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264575A (en) * 1979-07-16 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264577A (en) * 1979-08-03 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4485814A (en) * 1979-09-05 1984-12-04 Yoon In B One-piece compound elastic occluding member
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4384960A (en) * 1979-11-13 1983-05-24 Polley R D Iodine dispenser and method of dispensing iodine
WO1981001650A1 (en) * 1979-12-17 1981-06-25 Dow Corning Silicone gel-filled silicone rubber article possessing reduced surface-bleed
US4341728A (en) * 1979-12-20 1982-07-27 The Population Council, Inc. Method for making an IUD with shrinking of a medicated attachment onto a support
US4304226A (en) * 1980-03-03 1981-12-08 The Procter & Gamble Company Vaginal contraceptive
US4309776A (en) * 1980-05-13 1982-01-12 Ramon Berguer Intravascular implantation device and method of using the same
EP0050867A1 (en) * 1980-10-28 1982-05-05 Schering Aktiengesellschaft Vaginal ring
EP0056697A3 (en) * 1981-01-09 1984-09-19 Robert W. Rand Injectable compositions and apparatus suitable for use in inductively heating neoplasms
US4435180A (en) 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4555398A (en) * 1982-10-05 1985-11-26 Chisso Corporation Sustained-release vasodilator
WO1986001415A1 (en) * 1984-09-06 1986-03-13 Holmes, Michael, John Device for inserting in wounds and wound cavities
US4960415A (en) * 1984-09-06 1990-10-02 Merck Patent Gmbh Device for inserting in wounds and wound cavities
US4731080A (en) * 1985-01-18 1988-03-15 Galin Miles A Coated intraocular lens
US4888009A (en) * 1985-04-05 1989-12-19 Abiomed, Inc. Prosthetic heart valve
WO1987000042A1 (en) * 1985-07-02 1987-01-15 Rutgers, The State University Of New Jersey Transdermal verapamil delivery device
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
EP0219076A3 (en) * 1985-10-11 1988-04-20 Sumitomo Pharmaceuticals Company, Limited Sustained release composition
US4985253A (en) * 1985-10-11 1991-01-15 Sumitomo Pharmaceuticals Company, Limited Sustained release composition for pharmaceutical substances comprising a silicone elastomer carrier
AU594088B2 (en) * 1985-10-11 1990-03-01 Sumitomo Pharmaceuticals Company, Limited Sustained release composition
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US5008112A (en) * 1985-12-16 1991-04-16 International Minerals & Chem. Corporation Device for the extended delivery of diffusible agents
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
US5422118A (en) * 1986-11-07 1995-06-06 Pure Pac, Inc. Transdermal administration of amines with minimal irritation and high transdermal flux rate
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
US4894231A (en) * 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
WO1989000839A1 (en) * 1987-07-28 1989-02-09 Biomeasure, Incorporated Therapeutic agent delivery system
US4973320A (en) * 1987-08-04 1990-11-27 Firma Carl Freudenberg Tissue-compatible medical device and method for manufacturing the same
GB2216795A (en) * 1988-03-17 1989-10-18 Erba Carlo Spa Controlled release siloxane matrices with non-uniform internal drug distribution
GB2216795B (en) * 1988-03-17 1991-12-11 Erba Carlo Spa Siloxane matrices with internal non-uniform drug distribution
US4951657A (en) * 1988-04-22 1990-08-28 Dow Corning Corporation Heat sealable membrane for transdermal drug release
US5342693A (en) * 1988-06-08 1994-08-30 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coating and methods of manufacture
US5182317A (en) * 1988-06-08 1993-01-26 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
US5262451A (en) * 1988-06-08 1993-11-16 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
WO1989012478A1 (en) * 1988-06-25 1989-12-28 Just Hansjoerg Dilatation catheter
US20030195617A1 (en) * 1988-10-04 2003-10-16 Cordis Corporation Expandable intraluminal graft
US20060149353A1 (en) * 1988-10-04 2006-07-06 Schatz Richard A Expandable intraluminal graft
US5141748A (en) * 1989-02-17 1992-08-25 Hoffmann-La Roche, Inc. Implant drug delivery device
WO1990013332A1 (en) * 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
US5100422A (en) * 1989-05-26 1992-03-31 Impra, Inc. Blood vessel patch
US5104400A (en) * 1989-05-26 1992-04-14 Impra, Inc. Blood vessel patch
US5152782A (en) * 1989-05-26 1992-10-06 Impra, Inc. Non-porous coated ptfe graft
US4955899A (en) * 1989-05-26 1990-09-11 Impra, Inc. Longitudinally compliant vascular graft
US5219580A (en) * 1989-06-08 1993-06-15 Rhone-Poulenc Chimie Thermoplastic silicone shaped articles for controlled release of iodine values to domestic water supplies
US6645241B1 (en) 1992-07-08 2003-11-11 Ernst Peter Strecker Endoprosthesis that can be percutaneously implanted in the patient's body
US20040049259A1 (en) * 1992-07-08 2004-03-11 Strecker Ernst Peter Endoprosthesis that can be percutaneously implanted in the patient's body
US8067022B2 (en) 1992-09-25 2011-11-29 Boston Scientific Scimed, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US5591445A (en) * 1992-12-09 1997-01-07 Regents Of The University Of Minnesota Smooth muscle chemical pacemaker
US5340583A (en) * 1993-05-06 1994-08-23 Allergan, Inc. Antimicrobial lenses and lens care systems
US5515117A (en) * 1993-05-06 1996-05-07 Allergan, Inc. Antimicrobial lenses and lens care systems
US8158670B2 (en) 1995-02-15 2012-04-17 Boston Scientific Scimed, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US8097642B2 (en) 1995-02-15 2012-01-17 Boston Scientific Scimed, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US20020071902A1 (en) * 1995-04-19 2002-06-13 Ni Ding Drug release stent coating
US20040049265A1 (en) * 1995-04-19 2004-03-11 Schneider (Usa) Inc. Drug coating with topcoat
US20050187611A1 (en) * 1995-04-19 2005-08-25 Boston Scientific Scimed, Inc. Drug coating with topcoat
US5810836A (en) * 1996-03-04 1998-09-22 Myocardial Stents, Inc. Device and method for trans myocardial revascularization (TMR)
US7229473B2 (en) 1997-04-18 2007-06-12 Cordis Corporation Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent
US7223286B2 (en) 1997-04-18 2007-05-29 Cordis Corporation Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent
US7217286B2 (en) 1997-04-18 2007-05-15 Cordis Corporation Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent
US20060282160A1 (en) * 1997-04-18 2006-12-14 Cordis Corporation Local Delivery of Rapamycin for Treatment of Proliferative Sequelae Associated with PTCA Procedures, Including Delivery Using a Modified Stent
US6168801B1 (en) 1998-09-09 2001-01-02 Cardiac Pacemakers, Inc. Controlled release drug delivery
US6756048B1 (en) 1998-09-10 2004-06-29 Sumitomo Pharmaceuticals Company, Limited Long time drug-sustained release preparation
WO2000029464A1 (en) * 1998-11-12 2000-05-25 Leiras Oy Novel membrane or matrix for controlling drug permeation
US7218971B2 (en) 1999-03-29 2007-05-15 Cardiac Pacemakers, Inc. Implantable lead with dissolvable coating for improved fixation and extraction
US20040215306A1 (en) * 1999-03-29 2004-10-28 Cardiac Pacemakers, Inc. Implantable lead with dissolvable coating for improved fixation and extraction
US6304786B1 (en) 1999-03-29 2001-10-16 Cardiac Pacemakers, Inc. Implantable lead with dissolvable coating for improved fixation and extraction
US6584363B2 (en) 1999-03-29 2003-06-24 Cardiac Pacemakers, Inc. Implantable lead with dissolvable coating for improved fixation and extraction
US7601363B2 (en) 1999-11-10 2009-10-13 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release drug formulations
US7247312B1 (en) 1999-11-10 2007-07-24 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release drug formulations for implantation
US20070166377A1 (en) * 1999-11-10 2007-07-19 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release drug formulations
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8303609B2 (en) 2000-09-29 2012-11-06 Cordis Corporation Coated medical devices
US20160158146A1 (en) * 2001-03-15 2016-06-09 United States of America, Department of Health & Human Services, Represented by the Secretary, C/O Ocular therapeutic agent delivery devices and methods for making and using such devices
US7625410B2 (en) 2001-05-02 2009-12-01 Boston Scientific Scimed, Inc. Stent device and method
US8197839B2 (en) * 2001-06-29 2012-06-12 Virbac Corporation Sustained release delivery system
US20040241204A1 (en) * 2001-06-29 2004-12-02 Martinod Serge R. Sustained release pharmaceutical composition
US20040247643A1 (en) * 2001-06-29 2004-12-09 Martinod Serge R Sustained release delivey system
US20040234572A1 (en) * 2001-09-11 2004-11-25 Martinod Serge R. Preparation of sustained release pharmaceutical composition
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
US8691264B2 (en) 2002-02-08 2014-04-08 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US20040022824A1 (en) * 2002-07-31 2004-02-05 Scimed Life Systems, Inc. Controlled drug delivery
US20040260272A1 (en) * 2002-10-22 2004-12-23 Friedman Craig D. Method and system for intravesicular delivery of therapeutic agents
EP1553899A4 (en) * 2002-10-22 2006-10-25 METHOD AND SYSTEM FOR INTRAVASCULAR DELIVERY OF THERAPEUTIC AGENTS
US7803395B2 (en) 2003-05-15 2010-09-28 Biomerix Corporation Reticulated elastomeric matrices, their manufacture and use in implantable devices
US20060147371A1 (en) * 2003-10-31 2006-07-06 Tuszynski Jack A Water-soluble compound
US20060034943A1 (en) * 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
US7763077B2 (en) 2003-12-24 2010-07-27 Biomerix Corporation Repair of spinal annular defects and annulo-nucleoplasty regeneration
US8750983B2 (en) 2004-09-20 2014-06-10 P Tech, Llc Therapeutic system
US20060064082A1 (en) * 2004-09-20 2006-03-23 Bonutti Peter M Minimally invasive therapeutic system
US10639052B2 (en) 2004-09-20 2020-05-05 P Tech, Llc Acoustic therapy device
US11534187B2 (en) 2004-09-20 2022-12-27 P Tech, Llc Acoustic therapy device
US9474676B2 (en) 2004-09-20 2016-10-25 P Tech, Llc Acoustic therapy device
WO2006037182A1 (en) 2004-10-06 2006-04-13 Agri-Biotech Pty Ltd Antibody production method
US20070141106A1 (en) * 2005-10-19 2007-06-21 Bonutti Peter M Drug eluting implant
EP2089486A4 (en) * 2006-11-21 2010-06-16 Steven J Ferry COATING SYSTEM
US20100076113A1 (en) * 2008-09-19 2010-03-25 Mentor Corporation Coating with antimicrobial agents
US8420153B2 (en) * 2008-09-19 2013-04-16 Mentor Worldwide Llc Coating with antimicrobial agents
US8419793B2 (en) * 2008-09-19 2013-04-16 Mentor Worldwide Llc Coating with antimicrobial agents
US20100198350A1 (en) * 2008-09-19 2010-08-05 Mentor Worldwide Llc Coating with antimicrobial agents
US20140021270A1 (en) * 2012-07-19 2014-01-23 National Institute Of Standards And Technology Vapor capture and release systems
US10315019B2 (en) 2013-03-15 2019-06-11 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US10286199B2 (en) 2013-03-15 2019-05-14 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US12409304B2 (en) 2013-03-15 2025-09-09 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US11285304B2 (en) 2013-03-15 2022-03-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US20230059851A1 (en) * 2014-06-06 2023-02-23 Nanovault Medical Llc Implantable cellular and biotherapeutic agent delivery canister
US11857672B2 (en) 2014-06-06 2024-01-02 Nanovault Medical, Llc Implantable cellular and biotherapeutic agent delivery canister
US12246085B2 (en) 2014-06-06 2025-03-11 Nanovault Medical Llc Implantable cellular and biotherapeutic agent delivery canister
US11857673B2 (en) * 2014-06-06 2024-01-02 Nanovault Medical, Llc Implantable cellular and biotherapeutic agent delivery canister
US11857670B2 (en) 2014-06-06 2024-01-02 Nanovault Medical, Llc Implantable cellular and biotherapeutic agent delivery canister
US11324935B2 (en) 2014-08-19 2022-05-10 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
EP3597176A1 (en) 2014-08-19 2020-01-22 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
US11918770B2 (en) 2014-08-19 2024-03-05 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
US10912933B2 (en) 2014-08-19 2021-02-09 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
WO2019079869A1 (pt) * 2017-10-26 2019-05-02 Sarraff Berger Rodrigo Otavio Implante com reservatório contendo microporos de liberação prolongada para aplicação subdérmica com propriedades termoelásticas e termostática e uso do dito implante
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CN114149688A (zh) * 2021-11-19 2022-03-08 北京理工大学 一种肌肉等效材料及其制备方法和应用

Also Published As

Publication number Publication date
CH483471A (de) 1969-12-31
DE1467861A1 (de) 1969-01-30
BR6352320D0 (pt) 1973-07-17
FR1381318A (fr) 1964-12-14
AU274375B2 (en) 1967-04-07
AU3461463A (en) 1965-03-04
GB998794A (en) 1965-07-21
FR8424M (en:Method) 1971-07-08

Similar Documents

Publication Publication Date Title
US3279996A (en) Polysiloxane carrier for controlled release of drugs and other agents
US3946734A (en) Apparatus for controlling the release of a drug
US4230686A (en) Drug excipient of silicone rubber
US3887699A (en) Biodegradable polymeric article for dispensing drugs
Mashak et al. Silicone polymers in controlled drug delivery systems: a review
KR100576583B1 (ko) 서방성 약물 송달 장치용 속도 조절막
Blackshear Implantable drug-delivery systems
US5480653A (en) Formulations for sustained release dressings and their use
US3920805A (en) Pharmaceutical devices and method
US4012497A (en) Drug excipient of silicone rubber
JP5368497B2 (ja) ポリウレタンを基とするポリマーを用いた長期薬物輸送装置の製造
US3089815A (en) Injectable pharmaceutical preparation, and a method of making same
Graham Polymeric inserts and implants for the controlled release of drugs
JPS60181015A (ja) 活性物質の持続放出用装置
JPH05501968A (ja) 薬剤または他の液剤投与のための植込可能な装置
GB1462958A (en) Biodegradable implantable drug delivery device and process for preparing and using the same
JPH03167116A (ja) 徐放性エレメントおよびその製造方法
US5558877A (en) Method and device for treatment of cancer
RU2463079C2 (ru) Разделительные агенты для имплантируемого устройства и способы их применения
Graham et al. Polymeric inserts and implants for the controlled release of drugs
EA032208B1 (ru) Система доставки лекарств
DE1467861C (de) Verwendung von Organopolysiloxan elastomeren als A^zneimitteltrager in fester Form
Samipour et al. Functional nanoporous membranes for drug delivery
JPH02212418A (ja) 治療剤含有微粒子
JPH0226602B2 (en:Method)